Ensysce Biosciences Inc (ENSC)

$0.37 0.00 (-1.19%)
Market Cap 7.26M
Revenue (ttm) 5.07M
Net Income (ttm) -10.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.79%
Debt to Equity Ratio 0.00
Volume 778,100
Avg Vol 18,146,879
Day's Range N/A - N/A
Shares Out 19.46M
Stochastic %K 24%
Beta 0.84
Analysts Strong Buy
Price Target $8.25

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4196
Address:
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States
StockDreamin
StockDreamin Aug. 24 at 4:42 PM
$ENSC https://youtu.be/CEeqCbEFIJw?is=fzIThgsMvi0JLorj
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 4:34 PM
$ENSC r/s or delist news coming soon!...Im gonna need some pain killers!
0 · Reply
Millerandybr
Millerandybr Aug. 24 at 3:36 PM
$ENSC got to fucking love companies that have their heads buried so far up their own asses that they just destroy investors... theft is what it is or in broader terms we call it fraud
0 · Reply
tradingatnight
tradingatnight Aug. 24 at 3:16 PM
$ENSC sold all. -57% loss. Was up 462% this year. Wiped half of that. One bad trade w shit exit strategy can ruin all gains and mental. Never trade emotionally. Take the losses. Stop “hoping” and “praying” when money and logic has to be involved. “Praying” and “hoping” will never do you good in the market. If you catch yourself saying that, know that even if not this trade, but some trade in the future will wipe all of your gains. Do your DD and remain sharp. It’s you VS world.
0 · Reply
ttttttesty
ttttttesty Aug. 24 at 2:59 PM
$ENSC delisted! Lynn's scam is over.
2 · Reply
ttttttesty
ttttttesty Aug. 24 at 2:56 PM
Delist $ENSC !! Make new ticker for CY not $CY.
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 2:55 PM
$ENSC not lookin good folks!...ive been caught in a few bios...They all use the same handbook...This is following the same pattern of disappointment! Bad news is coming!
1 · Reply
FreePoorR
FreePoorR Aug. 24 at 2:28 PM
$ENSC heading to Nazi’s gas chambers..🤣🤣🤣
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 11:52 AM
$ENSC What's the plan for compliance?
4 · Reply
tradingatnight
tradingatnight Aug. 24 at 1:17 AM
$ENSC might pump tmr because I doubt they are gonna let it delist and a lot of ppl expencting a delist
2 · Reply
Latest News on ENSC
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Aug 20, 2026, 8:00 AM EDT - 4 days ago

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Ensysce Biosciences Transcript: Investor update

Aug 18, 2026, 11:00 AM EDT - 6 days ago

Ensysce Biosciences Transcript: Investor update

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026, 4:15 PM EDT - 10 days ago

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Ensysce Biosciences Earnings release: Q2 2026

Ensysce Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Ensysce Biosciences Quarterly report: Q2 2026

Ensysce Biosciences completes acquisition of Cy Biopharma

2026-08-06T12:50:17.000Z - 18 days ago

Ensysce Biosciences completes acquisition of Cy Biopharma

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Aug 6, 2026, 8:00 AM EDT - 18 days ago

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Ensysce Biosciences Slides: Investor presentation

Aug 5, 2026, 9:00 AM EDT - 19 days ago

Ensysce Biosciences Slides: Investor presentation

Ensysce Biosciences awarded $5.3M installment in NIDA funding

2026-07-14T12:30:41.000Z - 5 weeks ago

Ensysce Biosciences awarded $5.3M installment in NIDA funding

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Jul 14, 2026, 8:00 AM EDT - 5 weeks ago

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102

2026-06-26T12:05:15.000Z - 2 months ago

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

2026-06-04T20:45:12.000Z - 2 months ago

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

Ensysce Biosciences Registration statement: Registration filing

Jun 4, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Registration statement: Registration filing

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026, 4:15 PM EDT - 3 months ago

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Ensysce Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Ensysce Biosciences Quarterly report: Q1 2026

Ensysce Biosciences Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Ensysce Biosciences Earnings release: Q1 2026

Ensysce announces expansion of patent protection for MPAR technology

2026-05-12T15:40:41.000Z - 3 months ago

Ensysce announces expansion of patent protection for MPAR technology

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

May 12, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

R

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

May 8, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Ensysce Biosciences Slides: Investor presentation

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Ensysce Biosciences Slides: Investor presentation

Ensysce secures IRB approval of final phase of PF614-MPAR-102 study

2026-04-16T13:08:30.000Z - 4 months ago

Ensysce secures IRB approval of final phase of PF614-MPAR-102 study

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Registration statement: Registration filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Registration statement: Registration filing

Ensysce Biosciences files to sell 20.34M shares of common stock for holders

2026-04-09T10:12:51.000Z - 4 months ago

Ensysce Biosciences files to sell 20.34M shares of common stock for holders

Ensysce Biosciences secures second financing from 2025 agreement

2026-04-07T12:52:56.000Z - 4 months ago

Ensysce Biosciences secures second financing from 2025 agreement

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 30, 2026, 4:50 PM EDT - 5 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Ensysce Biosciences Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

Ensysce Biosciences Annual report: Q4 2025

Ensysce Biosciences Earnings release: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

Ensysce Biosciences Earnings release: Q4 2025

Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series

2026-03-04T13:51:12.000Z - 6 months ago

Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Mar 4, 2026, 8:45 AM EST - 6 months ago

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Ensysce Biosciences announces publication on MPAR technology

2026-03-03T13:32:48.000Z - 6 months ago

Ensysce Biosciences announces publication on MPAR technology

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Mar 3, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Ensysce Biosciences initiates review of strategic alternatives

2026-02-25T13:17:50.000Z - 6 months ago

Ensysce Biosciences initiates review of strategic alternatives

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 25, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Feb 23, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614

2026-01-28T13:26:39.000Z - 7 months ago

Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 28, 2026, 8:00 AM EST - 7 months ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Ensysce Biosciences expands global opioid patent portfolio

2026-01-21T13:15:40.000Z - 7 months ago

Ensysce Biosciences expands global opioid patent portfolio

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 21, 2026, 8:00 AM EST - 7 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Ensysce Biosciences receives EU patent for ADHD therapy

2026-01-08T13:52:10.000Z - 8 months ago

Ensysce Biosciences receives EU patent for ADHD therapy

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 8, 2026, 8:00 AM EST - 8 months ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Ensysce Biosciences Transcript: AGM 2025

Jan 7, 2026, 12:00 PM EST - 8 months ago

Ensysce Biosciences Transcript: AGM 2025

Ensysce Biosciences CEO says ‘positioned for continued momentum’

2026-01-05T14:30:53.000Z - 8 months ago

Ensysce Biosciences CEO says ‘positioned for continued momentum’

Ensysce Biosciences Issues Annual Shareholder Letter

Jan 5, 2026, 8:00 AM EST - 8 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 16, 2025, 7:00 AM EST - 8 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 12, 2025, 8:00 AM EST - 9 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614

2025-12-09T13:25:51.000Z - 9 months ago

Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 9, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Ensysce Biosciences files to sell 4.6M shares of common stock for holders

2025-12-02T22:00:54.000Z - 9 months ago

Ensysce Biosciences files to sell 4.6M shares of common stock for holders

Ensysce Biosciences issued notice of allowance for MPAR tech patent

2025-12-02T13:35:42.000Z - 9 months ago

Ensysce Biosciences issued notice of allowance for MPAR tech patent

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Dec 2, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Ensysce Biosciences Registration statement: Registration Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Registration statement: Registration Filing

Ensysce Biosciences Proxy statement: Proxy Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Ensysce Biosciences receives FDA feedback on PF614 manufacturing

2025-11-20T13:36:22.000Z - 9 months ago

Ensysce Biosciences receives FDA feedback on PF614 manufacturing

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 20, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Ensysce Biosciences secures $4M financing

2025-11-17T13:30:26.000Z - 10 months ago

Ensysce Biosciences secures $4M financing

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 17, 2025, 8:05 AM EST - 10 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:15 PM EST - 10 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Ensysce Biosciences Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 10 months ago

Ensysce Biosciences Earnings release: Q3 2025

Ensysce Biosciences Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 10 months ago

Ensysce Biosciences Quarterly report: Q3 2025

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Oct 10, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Ensysce Biosciences Slides: Investor Presentation

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Slides: Investor Presentation

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Ensysce Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Quarterly report: Q2 2025

Ensysce Biosciences Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q2 2025

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Quarterly report: Q1 2025

Ensysce Biosciences Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q1 2025

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 12, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences Registration statement: Registration Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Registration statement: Registration Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Ensysce Biosciences Registration statement: Registration Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Annual report: Q4 2024

Ensysce Biosciences Earnings release: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q4 2024

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

StockDreamin
StockDreamin Aug. 24 at 4:42 PM
$ENSC https://youtu.be/CEeqCbEFIJw?is=fzIThgsMvi0JLorj
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 4:34 PM
$ENSC r/s or delist news coming soon!...Im gonna need some pain killers!
0 · Reply
Millerandybr
Millerandybr Aug. 24 at 3:36 PM
$ENSC got to fucking love companies that have their heads buried so far up their own asses that they just destroy investors... theft is what it is or in broader terms we call it fraud
0 · Reply
tradingatnight
tradingatnight Aug. 24 at 3:16 PM
$ENSC sold all. -57% loss. Was up 462% this year. Wiped half of that. One bad trade w shit exit strategy can ruin all gains and mental. Never trade emotionally. Take the losses. Stop “hoping” and “praying” when money and logic has to be involved. “Praying” and “hoping” will never do you good in the market. If you catch yourself saying that, know that even if not this trade, but some trade in the future will wipe all of your gains. Do your DD and remain sharp. It’s you VS world.
0 · Reply
ttttttesty
ttttttesty Aug. 24 at 2:59 PM
$ENSC delisted! Lynn's scam is over.
2 · Reply
ttttttesty
ttttttesty Aug. 24 at 2:56 PM
Delist $ENSC !! Make new ticker for CY not $CY.
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 2:55 PM
$ENSC not lookin good folks!...ive been caught in a few bios...They all use the same handbook...This is following the same pattern of disappointment! Bad news is coming!
1 · Reply
FreePoorR
FreePoorR Aug. 24 at 2:28 PM
$ENSC heading to Nazi’s gas chambers..🤣🤣🤣
0 · Reply
StockDreamin
StockDreamin Aug. 24 at 11:52 AM
$ENSC What's the plan for compliance?
4 · Reply
tradingatnight
tradingatnight Aug. 24 at 1:17 AM
$ENSC might pump tmr because I doubt they are gonna let it delist and a lot of ppl expencting a delist
2 · Reply
ttttttesty
ttttttesty Aug. 24 at 12:31 AM
$ENSC Lynn had nothing to show for her 'clever science'.
0 · Reply
ttttttesty
ttttttesty Aug. 24 at 12:30 AM
$ENSC why did Lynn take so long to quit?
0 · Reply
Pelicanos
Pelicanos Aug. 24 at 12:29 AM
$ENSC
0 · Reply
ttttttesty
ttttttesty Aug. 23 at 11:59 PM
$ENSC is a worse scam than $NVVE (even after it was delisted).
0 · Reply
StockDreamin
StockDreamin Aug. 23 at 10:49 PM
$ENSC Predictions for tomorrow?
1 · Reply
ttttttesty
ttttttesty Aug. 23 at 10:01 PM
Delist that MOFO $ENSC .
0 · Reply
Sunnybhargava
Sunnybhargava Aug. 23 at 6:50 PM
$ENSC gower bought almost 1 million shares from his money in April that time float was 9 million. Funny. 😄 and he file it now in August. Totally inside trading.
1 · Reply
Sunnybhargava
Sunnybhargava Aug. 23 at 6:39 PM
$ENSC looks like we will see more filing from insider to buy more stocks soon till this stock rerate. They know what’s going on and lock the price to they can accumulate more and retail get scare. Sound like a plan
0 · Reply
Sunnybhargava
Sunnybhargava Aug. 23 at 5:52 PM
$ENSC 15 million NIDA and 25 million nah. Government grant total 40 million grant to make this drug. 77 million merger. 19 million float. At .37. Is a joke. Someone loading in pennies the stock worth 10-20x.
0 · Reply
ttttttesty
ttttttesty Aug. 22 at 10:48 PM
$ENSC Lynn was an amazing scammer. Her invisible "clever science" will never be forgotten. Makes you wanna run for cover!
1 · Reply
ttttttesty
ttttttesty Aug. 22 at 10:45 PM
$ENSC is a worse scam than $NNVE (even after it was delisted).
1 · Reply
ttttttesty
ttttttesty Aug. 22 at 10:44 PM
I can't believe peoeple are still falling for this $ENSC scam after the past 4 years. $ENSC will be delisted and scapegoating Lynn is going back to BJ's now that she's quit. There's nothing to bring to market but pain itself. The $77M departure-aquisition BS is a facade.
1 · Reply